FUJI PHARMA CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,529 JPY | +0.72% |
|
-4.56% | -12.08% |
| 2023 | Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump | MT |
| 2023 | Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan | MT |
ETFs positioned on Fuji Pharma Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.06% | 19 M€ | +11.51% | ||
| 0.00% | 45 M€ | 0.00% | - | |
| 0.00% | 17 M€ | +11.76% | - | |
| 0.00% | 140,441 M€ | +16.69% | ||
| 0.00% | 63,295 M€ | +16.72% | - | |
| 0.00% | 20,360 M€ | +15.55% | - |
Fuji Pharma Co., Ltd. is a Japan-based company mainly engaged in the manufacture and sale of medical products. The Company is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,518
JPY
Average target price
2,090
JPY
Spread / Average Target
+37.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.08% | 236M | |
| +30.70% | 588B | |
| -3.42% | 364B | |
| +18.02% | 326B | |
| +4.27% | 285B | |
| +14.75% | 239B | |
| +9.80% | 210B | |
| -7.81% | 200B | |
| +8.12% | 167B | |
| -1.42% | 161B |
- Stock Market
- Equities
- 4554 Stock
- Funds and ETFs Fuji Pharma Co., Ltd.
